196 related articles for article (PubMed ID: 17448964)
41. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand.
Dazzi F; Szydlo RM; Goldman JM
Exp Hematol; 1999 Oct; 27(10):1477-86. PubMed ID: 10517488
[TBL] [Abstract][Full Text] [Related]
42. Intrathecal application of donor lymphocytes in leukemic meningeosis after allogeneic stem cell transplantation.
Neumann M; Blau IW; Burmeister T; Tietze-Buerger C; Blau O; Gerbitz A; Uharek L; Thiel E
Ann Hematol; 2011 Aug; 90(8):911-6. PubMed ID: 21318573
[TBL] [Abstract][Full Text] [Related]
43. Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage.
Chaidos A; Kanfer E; Apperley JF
Best Pract Res Clin Haematol; 2007 Jun; 20(2):125-54. PubMed ID: 17448953
[TBL] [Abstract][Full Text] [Related]
44. First-Line management of CML: a state of the art review.
Hochhaus A
J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S1-S10. PubMed ID: 18397676
[TBL] [Abstract][Full Text] [Related]
45. [An advance in the treatment of CML].
Ohnishi K
Gan To Kagaku Ryoho; 2007 Dec; 34(13):2185-90. PubMed ID: 18079618
[TBL] [Abstract][Full Text] [Related]
46. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.
Loren AW; Porter DL
Bone Marrow Transplant; 2008 Mar; 41(5):483-93. PubMed ID: 18026156
[TBL] [Abstract][Full Text] [Related]
47. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
[TBL] [Abstract][Full Text] [Related]
48. Stem-cell transplantation in chronic lymphocytic leukaemia.
Gribben JG
Best Pract Res Clin Haematol; 2007 Sep; 20(3):513-27. PubMed ID: 17707837
[TBL] [Abstract][Full Text] [Related]
49. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?
Maziarz RT
Curr Opin Hematol; 2008 Mar; 15(2):127-33. PubMed ID: 18300759
[TBL] [Abstract][Full Text] [Related]
50. Prognosis of pediatric patients transplanted for Ph+ chronic myeloid leukemia in the period from 1989 to 2006 in the Czech Republic.
Krol L; Formankova R; Keslova P; Vavra V; Zemanova Z; Michalova K; Dobrovolna M; Moravcova J; Kobylka P; Ivaskova E; Navratilova J; Stary J; Sedlacek P
Neoplasma; 2008; 55(2):101-6. PubMed ID: 18237247
[TBL] [Abstract][Full Text] [Related]
51. [Allogeneic stem cell transplantation for patients with Philadelphia positive leukemia resistant to imatinib].
Han W; Liu KY; Xu LP; Chen H; Liu DH; Chen YH; Zhang XH; Zhang YC; Chen Y; Wang Y; Wang J; Lu DP; Huang XJ
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1974-7. PubMed ID: 19062738
[TBL] [Abstract][Full Text] [Related]
52. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
[TBL] [Abstract][Full Text] [Related]
53. Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT.
Ditschkowski M; Haferlach C; Schulte C; Trenschel R; Beelen DW
Bone Marrow Transplant; 2009 Aug; 44(4):265-6. PubMed ID: 19234516
[No Abstract] [Full Text] [Related]
54. Role of allogeneic transplantation in low-grade lymphoma and chronic lymphocytic leukemia.
Thomson KJ; Mackinnon S
Curr Opin Hematol; 2006 Jul; 13(4):273-9. PubMed ID: 16755225
[TBL] [Abstract][Full Text] [Related]
55. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation.
Smit WM; Rijnbeek M; van Bergen CA; Fibbe WE; Willemze R; Falkenburg JH
Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10152-7. PubMed ID: 9707616
[TBL] [Abstract][Full Text] [Related]
56. The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era.
Burke MJ; Willert J; Desai S; Kadota R
Pediatr Blood Cancer; 2009 Dec; 53(6):992-5. PubMed ID: 19621426
[TBL] [Abstract][Full Text] [Related]
57. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
[TBL] [Abstract][Full Text] [Related]
58. Donor lymphocyte infusion. An adaptive cellular immunotherapy for treatment of hematological malignancies.
Owaidah TM
Saudi Med J; 2003 Feb; 24(2):138-41. PubMed ID: 12682675
[TBL] [Abstract][Full Text] [Related]
59. Low-dose total body irradiation-based regimens as a preparative regimen for allogeneic haematopoietic cell transplantation in acute myelogenous leukaemia.
Al-Ali H; Cross M; Lange T; Freund M; Dölken G; Niederwieser D
Curr Opin Oncol; 2009 Jun; 21 Suppl 1():S17-22. PubMed ID: 19561407
[TBL] [Abstract][Full Text] [Related]
60. Treatment of leukemia relapse after allogeneic hematopoietic stem cell transplantation by donor lymphocyte infusion and STI-571.
Baron F; Frère P; Fillet G; Beguin Y
Haematologica; 2001 Sep; 86(9):993-4. PubMed ID: 11532632
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
